Biotechnology

Tradr 2X Long SNPS Daily ETF

Synaptogenix Renamed as TAO Synergies to Focus on Cryptocurrency and AI Integration

Synaptogenix Acquires TAO for Cryptocurrency Treasury Strategy

Synaptogenix's First Acquisition of TAO and Yield Generation through Staking

Synaptogenix Inc Launches TAO Token Acquisition Strategy

Synaptogenix released FY2025 Q1 earnings on May 15 (EST) with actual revenue of USD 0 and EPS of USD 0.04

Synaptogenix released FY2024 Q4 earnings on March 27 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -4.1667 USD (forecast -2.06 USD)

Synaptogenix released FY2024 annual earnings on March 27 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -10.99 USD (forecast -7.48 USD)

Synaptogenix released FY2024 Q3 earnings on November 12, 2024 (EST), with actual EPS -4.5823 (forecast -1.95)

Synaptogenix released FY2024 9 Months Earnings on November 12, 2024 (EST) with actual revenue of 0 and EPS of -6.1768

Synaptogenix: Maxim Group upgrades from Hold to Buy

Synaptogenix announces FDA approval of IND application for the use of Bryostatin-1 in clinical trials for multiple sclerosis

Synaptogenix released FY2023 annual earnings on April 1, 2024 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -29.5629 USD (forecast -39.5 USD)

Synaptogenix released FY2023 Q4 earnings on April 1 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -1.4513 USD (forecast -9.5 USD)

Synaptogenix released FY2023 cumulative Q3 earnings on November 14, 2023 (EST), with net income -12.55M USD and EPS -42.1054

< 1B

1B - 5B

5B - 10B

10B - 50B

50B - 100B

100B - 500B

500B - 1T

≥ 1T

Market Value

Total Assets

< 100M

100M - 500M

500M - 1B

≥ 100B

Revenue

0 - 50M

50M - 100M

≥ 10B

Profits

< 0%

0% - 5%

5% - 10%

10 - 15%

15% - 20%

20 - 25%

25% - 30%

>= 30%

ROE(TTM)

= 0%

0% - 1%

1% - 3%

3% - 5%

5% - 8%

8% - 10%

>= 10%

Dividend Yield

0% - 10%

10% - 15%

20% - 30%

30% - 40%

40% - 50%

>= 50%

Net Profit Margin

0 - 0.05

0.05 - 0.1

0.1 - 0.2

0.2 - 0.4

0.4 - 0.6

0.6 - 0.8

0.8 - 1

>= 1

Asset Turnover

< 1.5

1.5 - 2

2 - 3

3 - 5

5 - 10

10 - 15

15 - 20

>= 20

Equity Multiplier

< 10%

10% - 30%

30% - 50%

50% - 70%

70 - 80%

80% - 90%

90% - 95%

>= 95%

Debt Ratio

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

Foxx Development

Palatin Tech

Mobile-Health Network Solutions

Nuvve

Datavault AI

CCSC Tech

Iveda Solutions

Harrison Global

Alps

SNPX

LB filings

Tradr 2X Long SNPS Daily ETF | 10-Q: FY2025 Q3 Revenue: USD 203.37 K

Synaptogenix | 10-Q: FY2025 Q1 EPS: USD 0.04

TAOX

Synaptogenix Inc. has expanded its cryptocurrency treasury strategy by purchasing TAO, an AI token, and partnering with BitGo for enhanced digital asset management. This collaboration will utilize BitGo's custody, trading, and staking capabilities to generate token-based yield and secure assets through regulated cold storage. The company, led by James Altucher, has started staking TAO to generate revenue and enhance shareholder value.

Reuters

Tao Synergies

Synaptogenix Inc. Expands Blockchain Treasury with Strategic Investment in TAO, Partners with BitGo for Enhanced Digital Asset Management

Synaptogenix (NASDAQ: SNPX) has revealed its strategic move of deploying capital into TAO to enhance its blockchain treasury model. This initiative leverages BitGo's custody, trading, and staking capabilities to generate token-based yield. The company made the announcement from New York on June 24, 2025. This development marks the initial purchase by Synaptogenix as it drives forward with this new venture.

Unusual Whales

Strategy

Synaptogenix acquires TAO under Crypto Treasury Strategy, appoints BitGo as Custodian, starts yield generation through staking. #SNPX #BitGo #TAO

Synaptogenix Inc. has announced its acquisition of TAO as part of its cryptocurrency treasury strategy, focusing on AI and machine learning. BitGo has been appointed as the custodian for TAO holdings, ensuring secure storage and facilitating acquisitions through its trading platforms. This acquisition, funded by cash reserves, initiates revenue generation through TAO staking, highlighting Synaptogenix's commitment to its crypto strategy and long-term value creation.

Synaptogenix Inc. Announces Initial Acquisition of TAO as Part of Crypto Treasury Strategy, Partners with BitGo for Custody and Yield Generation

Klotho Neurosciences' latest animal experiment data shows that its therapy targeting the α-Klotho gene is expected to reverse multi-organ aging, with its stock price soaring 787% in the U.S. stock market. This news has sparked a fervent market enthusiasm for anti-aging concepts, with trading volume exceeding 1.1 billion shares, far surpassing the daily average. At the same time, Synaptogenix also saw its stock price rise over 44% due to investments in cryptocurrency. This event reflects the profound impact of innovation in the biotechnology sector on market dynamics

- Klotho Neurosciences announced early research results indicating its gene therapy may reverse age-related organ degeneration, leading to a 787% surge in its stock price.  
- The company's preclinical trials suggest that enhancing Klotho gene expression can slow down organ aging, attracting significant investor interest in the biotech sector.  
- However, the investment carries risks due to the current reliance on animal data, uncertain regulatory pathways, and the company's weak financial position, necessitating potential future funding rounds.

Zhitong

Klotho gene therapy is expected to reverse organ degeneration, with the stock price soaring 787% in a single day

June 9 (Reuters) - Synaptogenix Inc:* SYNAPTOGENIX INC: ON JUNE 8, ALAN J. TUCHMAN RESIGNED AS CEO AND DIRECTOR OF CO* SYNAPTOGENIX INC: TUCHMAN TO SERVE AS CHIEF MEDICAL OFFICER OF CO* SYNAPTOGENIX INC: ON JUNE 6, JOSHUA SILVERMAN APPOINTED AS EXECUTIVE CHAIRMAN OF CO’S BOARD OF DIRECTORS Source text: Further company coverage:

Synaptogenix Says On June 8, Alan Tuchman Resigned As CEO And Director Of Co

June 9 (Reuters) - Synaptogenix Inc:* SYNAPTOGENIX: LAUNCH OF DIFFERENTIATED CRYPTOCURRENCY TREASURY STRATEGY FOCUSED EXCLUSIVELY ON AI CRYPTO TOKEN "TAO"* SYNAPTOGENIX INC - PLANS INITIAL $10 MILLION TAO ACQUISITION, TARGETS $100 MILLION IN TAO TOKEN ACQUISITIONS* SYNAPTOGENIX INC - ENTERS $5.5 MILLION FINANCING AGREEMENT* SYNAPTOGENIX INC - SERIES D PREFERRED STOCK CONVERSION PRICE SET AT $3.00 PER SHARE Source text: Further company coverage:

Synaptogenix Launch Of Differentiated Cryptocurrency Treasury Strategy Focused Exclusively On AI Crypto Token 'TAO'

Synaptogenix Inc. has secured a $5.5 million equity investment through the sale of 5,500 shares of Series D convertible preferred stock, convertible into common stock at a price of $3.00 per share. The financing, involving investor James Altucher, is expected to close around June 10, 2025. This investment supports Synaptogenix's strategy to enhance its digital asset treasury, particularly focused on the AI token TAO.

Synaptogenix Inc. Secures $5.5 Million in Equity Investment Through Sale of Series D Convertible Preferred Stock

As of September 30, 2024, Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company, reported holding $19.6 million in cash and cash equivalents. The company anticipates a significant reduction in its cash burn rate. This information was announced in New York on December 20, 2024.

ING Groep

Nasdaq

Pathward Fin

Synaptogenix forms special committee to explore value creation opportunities; has $19.6 million in cash, reduced cash burn rate.

Synaptogenix, Inc. has formed a Special Committee to explore strategic opportunities for value creation, leveraging its strong financial position with $6 million in cash as of September 30, 2024. The company anticipates a significant reduction in its cash burn rate while considering collaborations for its Bryostatin-1 asset. Synaptogenix is focused on developing therapeutics for neurodegenerative disorders and has submitted a grant proposal to the NIH for Bryostatin-1's development.

StockTitan

News

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength | SNPX Stock News